PhaseV has announced the launch of the ClinOps platform, a next-generation solution designed to modernise clinical trial operations through precision-guided site selection and dynamic performance monitoring.
Built on causal machine learning and real-world patient-level data, the ClinOps platform enables study teams to move beyond historical benchmarks and make operational decisions with greater speed and accuracy.
“Our ClinOps platform provides a new standard for how trials are planned and executed,” said Raviv Pryluk, CEO and co-founder of PhaseV.
“We go much deeper than traditional feasibility and site selection tools, providing real-time visibility into the factors driving trial success and allowing trial teams to interact with their data in unprecedented ways. This provides execution teams with a new level of confidence as they make decisions that drive better outcomes.”
The ClinOps platform is the latest addition to PhaseV’s vertical AI solution, which is used by more than 30 pharma, biotech sponsors, and CROs across more than 20 therapeutic areas.
Conventional site selection tools typically rely on retrospective averages and static performance metrics. PhaseV takes a different approach, using causal machine learning to model the factors that drive site variability and patient heterogeneity. The ClinOps platform takes into account patient-level covariates, including age, BMI, ethnicity, comorbidities, genomics, and prior treatments, aligning with the mechanism of action (MoA) of the therapeutic asset and eligibility criteria. In this way, the platform provides data-driven recommendations for optimal trial sites, ensuring a higher probability of success, faster recruitment rates, and real-world patient diversity.
Instead of treating clinical trial feasibility as a one-time task, the ClinOps platform allows users to interactively explore global site recommendations based on specific trial parameters, therapeutic context, and target populations. The result is a more nuanced and adaptive process that improves participant representation, reduces enrollment risk, and minimises exposure to low-performing or congested sites.
Once a trial is under way, the ClinOps platform continues to play a key role through real-time site and trial performance monitoring. Operational teams can track shifting enrollment dynamics, assess site-level performance and detect emerging risks, all from a centralized, data-rich dashboard.
Predictive models uncover early indicators of site success or underperformance, while intelligent alerts help teams respond quickly to deviations or bottlenecks. With trend analysis across cohorts, timepoints, and geographies, study teams gain the insights needed to stay on track and act decisively.
Designed to support decision-making from protocol design to last patient out, the ClinOps platform enhances operational strategy at every phase of the trial life-cycle from pre-launch to post activation.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
